Arcadia Investment Management Corp MI Acquires Shares of 1,333 RxSight, Inc. (NASDAQ:RXST)

Arcadia Investment Management Corp MI acquired a new stake in shares of RxSight, Inc. (NASDAQ:RXST) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,333 shares of the company’s stock, valued at approximately $46,000.

Other large investors have also recently made changes to their positions in the company. Principal Financial Group Inc. grew its holdings in RxSight by 0.7% during the 3rd quarter. Principal Financial Group Inc. now owns 36,046 shares of the company’s stock valued at $1,782,000 after buying an additional 240 shares in the last quarter. Quarry LP boosted its position in shares of RxSight by 82.3% during the 3rd quarter. Quarry LP now owns 638 shares of the company’s stock valued at $32,000 after acquiring an additional 288 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of RxSight by 1.9% in the third quarter. The Manufacturers Life Insurance Company now owns 20,911 shares of the company’s stock valued at $1,034,000 after purchasing an additional 399 shares in the last quarter. MCIA Inc increased its position in RxSight by 5.7% in the third quarter. MCIA Inc now owns 8,459 shares of the company’s stock worth $385,000 after purchasing an additional 459 shares during the last quarter. Finally, KBC Group NV raised its stake in RxSight by 63.6% during the third quarter. KBC Group NV now owns 1,232 shares of the company’s stock valued at $61,000 after purchasing an additional 479 shares in the last quarter. 78.78% of the stock is owned by institutional investors.

RxSight Stock Performance

Shares of NASDAQ RXST opened at $29.60 on Friday. RxSight, Inc. has a fifty-two week low of $26.29 and a fifty-two week high of $66.54. The company has a market cap of $1.19 billion, a price-to-earnings ratio of -35.66 and a beta of 1.19. The business’s 50 day moving average price is $33.14 and its 200-day moving average price is $43.81.

Analyst Upgrades and Downgrades

A number of brokerages have commented on RXST. Jefferies Financial Group assumed coverage on shares of RxSight in a research note on Tuesday, October 29th. They issued a “buy” rating and a $72.00 price objective for the company. UBS Group initiated coverage on RxSight in a research report on Friday, December 6th. They issued a “buy” rating and a $52.00 price target for the company. Wells Fargo & Company decreased their price objective on RxSight from $42.00 to $40.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Stifel Nicolaus cut their target price on RxSight from $40.00 to $35.00 and set a “hold” rating on the stock in a research report on Monday, January 13th. Finally, Needham & Company LLC restated a “buy” rating and issued a $66.00 price target on shares of RxSight in a research report on Monday, January 13th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, RxSight currently has an average rating of “Moderate Buy” and a consensus price target of $58.13.

Insider Buying and Selling at RxSight

In other news, Director Jesse Anderson Corley purchased 1,443 shares of the stock in a transaction that occurred on Wednesday, January 15th. The stock was purchased at an average price of $31.18 per share, for a total transaction of $44,992.74. Following the completion of the acquisition, the director now owns 1,443 shares of the company’s stock, valued at approximately $44,992.74. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Shweta Maniar sold 3,782 shares of the stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $45.88, for a total value of $173,518.16. Following the completion of the transaction, the director now directly owns 10,902 shares in the company, valued at approximately $500,183.76. This trade represents a 25.76 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 13,506 shares of company stock valued at $567,456 in the last quarter. 9.36% of the stock is owned by insiders.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.